GLMD Eocene Ltd.
3.400USD-2.30%Mkt Cap: 4.95M $P/E: —20d ago
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic …
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.27BUSDP/E 30.7
$22.99BUSDP/E 14.5
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
Key Statistics
Company
Market Cap4.95M USD
Enterprise Value-7.49M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.31M USD
Revenue/Share—
Last Price3.400 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.50
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.36
EPS (TTM)-14.29
EPS (Forward)-1.03
52W Range
0.411059% of range5.450
52W High5.450 USD
52W Low0.4110 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-65.32%
ROA-55.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.32M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-106.65%
Net Debt-11.10M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity1.01
Current Ratio4.16
Quick Ratio4.11
Book Value/Sh12.72 USD
Cash/Share11.21 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.07M
Float975.79K
Insiders3.04%
Institutions1.89%
Technical
SMA 503.655 (-7.0%)
SMA 2003.655 (-7.0%)
Beta0.67
S&P 52W Chg16.45%
Avg Vol (30d)47.49K
Avg Vol (10d)5.94K
Technical Indicators
RSI (14)48.9
MACD0.2316
MACD Signal0.4208
MACD Hist.-0.1893
BB Upper4.810 USD
BB Middle4.063 USD
BB Lower3.316 USD
BB Width36.76%
ATR (14)0.6585 USD
Vol Ratio (20d)0.13x